Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Applied nutritional investigation

Increased risk for COVID-19 in patients with vitamin D deficiency

Joseph Katz D.M.D. a,⁎, Sijia Yue M.Sc. b, Wei Xue Ph.D. b

a Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, Florida, USA
b Department of Biostatistics, College of Public Health and Health Professionals, University of Florida, Gainesville, Florida, USA

A R T I C L E   I N F O

Article History:
Received 31 October 2020
Received in revised form 25 November 2020
Accepted 30 November 2020

Keywords:
COVID-19
vitamin D
dental disease
odds ratio
corona virus 19

A B S T R A C T

Objective: The 2019 coronavirus disease (COVID-19) pandemic has disproportionally affected a variety of patients with underlying risk factors such as respiratory and cardiovascular diseases, diabetes, obesity, and black race. Vitamin D deficiency, which can result in a compromised immune response, has been also linked to increased risk and increased morbidities associated with COVID-19. In the absence of large-scale longitudinal studies to determine the strength of association between vitamin deficiency and COVID-19, cross-sectional studies of large patient cohorts can be used.

Methods: We used the i2b2 patient’s registry platform at the University of Florida Health Center to generate a count of patients using the international classification of diseases (ICD)-10 diagnosis codes for the period of October 1, 2015, through June 30, 2020. Logistic regression of the aggregates was used for the analysis.

Results: Patients with vitamin D deficiency were 4.6 times more likely to be positive for COVID-19 (indicated by the ICD-10 diagnostic code COVID19) than patients with no deficiency (P < 0.001). The association decreased slightly after adjusting for sex (odds ratio [OR] = 4.58; P < 0.001) and malabsorption (OR = 4.46; P < 0.001), respectively. The association decreased significantly but remained robust (P < 0.001) after adjusting for race (OR = 3.76; P < 0.001), periodontal disease status (OR = 3.64; P < 0.001), diabetes (OR = 3.28; P < 0.001), and obesity (OR = 2.27; P < 0.001), respectively. In addition, patients with vitamin D deficiency were 5 times more likely to be infected with COVID-19 than patients with no deficiency after adjusting for age groups (OR = 5.155; P < 0.001).

Conclusions: Vitamin D deficiency is significantly associated with increased risk for COVID-19.

© 2020 Elsevier Inc. All rights reserved.

Introduction

Vitamin D is not a vitamin in the traditional sense. Rather, it is a group of fat-soluble compounds responsible for intestinal absorption of calcium, magnesium, and phosphate, and for a variety of additional biological effects [1]. Low levels of vitamin D can increase the likelihood of developing multiple acute and chronic ailments including cardiovascular and autoimmune diseases, diabetes, cancer, infectious diseases, dental caries (DC) [2], and periodontal disease (PD) [3,4]. In most people, more than 80% of vitamin D is formed in the skin after exposure to sunlight [2]. Hypovitaminosis D status usually reflects deficient sunlight exposure, deficient dietary intake, or both [2].

Recently, vitamin deficiency was linked with susceptibility to COVID-19 and severity of outcomes for patients with COVID-19 [5]. A few studies have presented conflicting results on the association between vitamin D deficiency and viral respiratory infection, partially because of the heterogeneity of the population studied and failure to adjust for comorbidities [6,7]. Many retrospective studies have found an association between vitamin D levels and COVID-19 severity and mortality [8,9]. Studies in the pediatric population demonstrated that patients with COVID-19 had significantly lower vitamin D levels compared with controls [10]. In addition, fever was significantly higher in patients who had deficient vitamin D levels compared with patients who had sufficient levels [10,11]; additionally, older adults with vitamin D deficiency and COVID-19 had worse morbidity outcomes compared with those who were not vitamin D deficient [12]. A prospective, interventional study found that a high dose of calcifediol reduced the need for intensive care stays in patients infected with COVID-19 [13].
A few studies have also reported on a significant association between sun exposure, vitamin D, and susceptibility to and recovery from COVID-19 [14,15]. Overall, significant controversy exists in the literature on the role of vitamin D deficiency in the prevention and treatment of COVID-19 and its effects on the severity of COVID-19 symptoms [16,17].

The present study investigated the patient registry of a large health center, examining the strength of the association between vitamin D deficiency and COVID-19 after adjusting for likely covariates, such as demographic characteristics and inflammation-associated comorbidities.

Materials and methods

The study was exempted by the University of Florida (UF) Institutional Review Board as the study did not include personal health information. The UF i2b2 patient registry platform, which provides data aggregates from patient visits from various UF health centers, was used for the study. We searched the international classification of diseases (ICD)-10 diagnosis codes that occurred during the period of October 1, 2015, through June 30, 2020, for vitamin D deficiency (codes E55.9, diabetes E10-E14, obesity E65-E68, malabsorption K90, caries K02, periodontal disease K05, and periapical abscesses K04 and COVID-19 U07.1 that occurred during 2020 before June 30, 2020. The demographic data was provided by the platform. The odds ratio (OR) for the associations were calculated by logistic regression of the aggregates using SAS statistical software. The 95% confidence interval (CI) and P value for each OR were tabulated. P < 0.05 was deemed significant.

Power analysis was completed with the assumption that 24% of the population has vitamin D deficiency [18] with the incidence of COVID-19 at 0.4% [19]. A total sample of 16 540 (4135 in the vitamin D deficiency group and 12 405 in the group with no vitamin D deficiency) achieve 80.001% power to detect a difference between the group COVID-19 incidence of 0.4%. The test statistic used is the two-sided t test. The significance level of the test is 0.0500 [20].

Results

From a total population of 98 7849 patients, 887 were positively diagnosed with COVID-19, 31 950 were diagnosis of vitamin D deficiency, and 87 patients had both vitamin D deficiency and COVID-19. This subgroup of 87 patients was composed of 98% adults, 71.3% males, and 88% black or other non-white individuals (Table 1). Patients with vitamin D deficiency were 4.6 times more likely to have a positive COVID-19 status than patients with no deficiency (95% CI, 3.713–5.783; P < 0.001). The association decreased slightly after adjusting for sex (OR = 4.58; 95% CI, 3.668–5.726; P < 0.001) and malabsorption (OR = 4.46; 95% CI, 3.554–5.599; P < 0.001), respectively, and for PA and DC status (OR = 3.92; 95% CI, 3.157–4.862; P < 0.001), diabetes (OR = 3.28; 95% CI, 2.591–4.151; P < 0.001), and obesity (OR = 2.27; 95% CI, 1.787–2.872; P < 0.001), respectively. The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased slightly after adjusting for sex (OR = 4.58; 95% CI, 3.668–5.726; P < 0.001) and for PA and DC status (OR = 3.92; 95% CI, 3.157–4.862; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively). The association decreased significantly but remained robust, with P < 0.001 after adjusting for age (OR = 3.76; 95% CI, 2.591–4.805; P < 0.001, respectively).

Discussion

In the present study, patients with vitamin D deficiency were 4.6 times (95% CI, 3.554–5.599) more likely to have a positive
COVID-19 status than patients with no deficiency. The association decreased significantly but remained robust, with $P$ value < 0.001 after adjusting for race (OR = 3.76; 95% CI, 2.98–4.73), PD status (OR = 3.92; 95% CI, 2.91–4.55), and obesity (OR = 2.27; 95% CI, 1.78–2.87), respectively (Fig. 1).

In addition to adjusting for known risk factors for COVID-19 such as diabetes [17], obesity [21], and intestinal malabsorption, which poses a risk for vitamin deficiency [22], we have adjusted for the presence of dental diseases DC, PD, and PA, which have recently been associated with COVID-19 [23]. The adjustments for dental diseases did not decrease the OR for COVID-19 dramatically, which supports the theory that dental disease and COVID-19 are both increased by vitamin D deficiency, as suggested by previous researchers [2–5].

Our data set included information on patients who were diagnosed with vitamin D deficiency over the period between October 1, 2015, and June 30, 2020, while the diagnosis of COVID-19 occurred in 2020. Using vitamin D levels obtained relatively recently (within the past 5 y) is a strength of this study. Research based on the 2006 to 2010 UK Biobank data for vitamin D levels only weakly supported the link between vitamin D deficiency and COVID-19 [9,24]. Researchers have challenged the claim that vitamin D levels are stable over time where the levels were assessed 10 to 14 y before the pandemic [24–26]. Rather than being stable, mean 25(OH)D levels were shown to increase significantly over 5 y, and the increase was driven by overall increases in vitamin D intake in the most vitamin D–deficient study participants [24–26].

This type of cross-sectional study cannot address the question of causality. Dental diseases, vitamin D deficiency, and COVID-19 share common confounding variables such as socioeconomic status and racial predisposition that may affect this association. It is noteworthy to mention that black patients are disproportionately affected by COVID-19, dental diseases, and vitamin D deficiency compared with other races [27,28], primarily because pigmentation reduces vitamin D production in the skin [29,30]. Vitamin D triggers the production of the antimicrobial proteins cathelicidins and defensins that can inhibit viral replication rates and reduce levels of cytokines that generate the inflammation responsible for the damage to the lining of the lungs, leading to acute respiratory disease [31]. Vitamin D also promotes the gene responsible for the expression of ACE2, which is down-regulated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [32].

### Table 2
Odds ratio for COVID-19 with vitamin D deficiency before and after adjustments for comorbidities and demographic covariates

|                | COVID-19 (n = 884) | Vitamin D deficiency (n = 31 950) | COVID-19 and vitamin D deficiency (n = 87) | Hospital (n = 987 849) |
|----------------|-------------------|----------------------------------|------------------------------------------|------------------------|
|                | Count             | %                               | Count                                   | Count                  | Count                   |
|                |                   |                                 |                                          |                        |                         |
| Sex            |                   |                                 |                                          |                        |                         |
| Male           | 499               | 56.4                            | 22 281                                   | 62                     | 71.3                    |
| Female         | 385               | 43.6                            | 9669                                    | 25                     | 28.7                    |
| Race           |                   |                                 |                                          |                        |                         |
| Black          | 225               | 26.6                            | 6215                                    | 33                     | 40.2                    |
| White          | 219               | 25.9                            | 2861                                    | 9                      | 11.0                    |
| Other          | 401               | 47.5                            | 2 2073                                  | 40                     | 48.8                    |
| Age            |                   |                                 |                                          |                        |                         |
| Age < 18       | 35                | 4.0                             | 1332                                    | 2                      | 2.0                     |
| Age 18–44      | 31                | 3.5                             | 10 346                                  | 31                     | 31.3                    |
| Age 45–64      | 206               | 23.5                            | 12 428                                  | 37                     | 37.4                    |
| Age > 64       | 173               | 19.7                            | 14 882                                  | 29                     | 29.3                    |

COVID-19, coronavirus disease 2019.

Fig 1. Confidence interval Barchart for logistic regression models.
In addition to the well-documented effect of vitamin D on the immune system, a recent study has demonstrated that sunlight may rapidly inactivate SARS-CoV-2 on surfaces, suggesting that there may be an environmental benefit associated with vitamin D as a result of sun exposure and that natural sunlight may be effective as a disinfectant for contaminated surfaces [15]. This study may support the hypothesis that some of the protective effect of vitamin D against COVID-19 may actually be attributed to sun exposure [15].

Because vitamin D deficiency has been shown to potentially increase the risk of severe respiratory infections, some investigators have suggested vitamin D supplements for prevention and treatment of COVID-19 complications, especially acute respiratory disease [33]. However, the National Institutes of Health found insufficient evidence to recommend for or against using vitamin D supplementation specifically to prevent or treat COVID-19, and recommended to continue the previous established recommendations on vitamin D supplementation for other reasons, such as bone and muscle health, because people may require supplementation because of lower sun exposure during the pandemic [34]. Nevertheless, recent systematic reviews and meta-analyses have concluded that vitamin D has potential in preventing respiratory infections, especially in those who have high levels of deficiency [35].

In our cross-sectional, retrospective study of patients' registry, we did not have access to the individual medical information that seems to be of importance for observational study. Data on the initial infection severity status, the COVID-19 treatments, and the length of vitamin D deficiency are therefore missing. Nevertheless, the main comorbidities and demographic covariates were retrieved and have been adjusted so that the strength of the association between vitamin D deficiency and COVID-19 could be established.

In conclusion, the present study has demonstrated that vitamin D deficiency is strongly associated with COVID-19 infection (P < 0.001), even after controlling for sex, malabsorption, dental diseases, race, diabetes, and obesity. Perhaps the most important finding was that vitamin D deficiency increased the risk of developing COVID-19 by a factor of 5 after adjusting for age. Prospective interventional studies are required to validate the hypothesis that vitamin D supplementation can be helpful for the prevention and treatment of COVID-19.

Acknowledgment

We acknowledge the University of Florida Integrated Data Repository (IDR) and the UF Health Office of the Chief Data Officer for providing the analytic data set for this project. Additionally, the research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under University of Florida Clinical and Translational Science Awards UL1 TR00064 and UL1TR00142.

References

[1] Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(6 Suppl):1678S–88S.

[2] Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 2017;18:153–65.

[3] Anbaricuoglu E, Kirtaloglu T, Ozturk A, Kolbakir F, Ackgoz G, Colak R. Vitamin D deficiency in patients with aggressive periodontitis. Oral Dis 2019;25:242–5.

[4] Uwitonze AM, Murereheje J, Inza MC, Harelimana EJ, Nasimihan U, Uwambye P, et al. Effects of vitamin D status on oral health. J Steroid Biochem Mol Biol 2018;175:190–4.

[5] Melzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw Open 2020;3:e2019722.

[6] Zittermann A, Pilz S, Hoffmann H, März W. Vitamin D and airway infections: a European perspective. Eur J Res Med 2016;21:14.

[7] Robertsen S, Grimes G, Melbye H. Association between serum 25-hydroxyvitamin D concentration and symptoms of respiratory tract infection in a Norwegian population: the Tromsø Study. Public Health Nutr 2014;17:780–6.

[8] Daneshkhab A, Agrawal V, Eshein A, Subramanian H, Roy HK, Backman V. Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients. Aging Clin Exp Res 2020;32(6):2141–58. https://doi.org/10.1007/s40526-020-01077-y.

[9] Darling AL, Blackburn DJ, Ahmad KR, Lanham-New SA. Very high prevalence of 25-hydroxyvitamin D deficiency in 6433 UK South Asian adults: analysis of the UK Biobank Cohort. Br J Nutr 2020;1:1–22. https://doi.org/10.1017/S0007114520002779.

[10] Yilmaz K, Şen V. Is vitamin D deficiency a risk factor for COVID-19 in children? Pediatr Pulmonol 2020;55:3595–601.

[11] Benskin LL. A basic review of the preliminary evidence that COVID-19 risk and severity is increased in vitamin D deficiency. Front Public Health 2020;8:513.

[12] Mandal AKJ, Baktash V, Hosack T, Missouri CS. Vitamin D status and COVID-19 in older adults. Aging Clin Exp Res 2020;32:2425–6.

[13] Estremas Castillo M, Estremas Costa LM, Vaqueiro Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. Effect of calcifiedol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol 2020;203:105751.

[14] Assyra A, Veruswati M. Sunlight exposure increased COVID-19 recovery rates: a study in the central pandemic area of Indonesia. Sci Total Environ 2020;729:139016.

[15] Ratnesar-Shumate S, Williams G, Green B, Krause M, Holland B, Wood S, et al. Simulated sunlight rapidly inactivates SARS-CoV-2 on surfaces. J Infect Dis 2020;222:214–22.

[16] Ali N. Role of vitamin D in preventing COVID-19 infection, progression and severity. J Infect Public Health 2020;13:1373–80.

[17] Singh AK, Gupta R, Gho A, Maira A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020;14:303–10.

[18] Armean K, Scherl M, Hofmann M, Neuwersch-Sommeregger S, Kostenberg M, Berisha AT, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020;74:1498–513.

[19] Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai S, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:755–65.

[20] Chow SC, Shao J, Wang H. Sample size calculations in clinical research. Boca Raton, Florida: Chapman & Hall/CRC; 2002 second edition.

[21] Zabetakis I, Lordan R, Norton C, Tsiopras A. COVID-19: the inflammation link and the role of nutrition in potential mitigation. Nutrients 2020;12:1466.

[22] Margules SL, Kuriyan D, Elliott MS, Han Z. Vitamin D deficiency in patients with intestinal malabsorption syndromes—think in and outside the gut. J Dig Dis 2015;16:817–33.

[23] Katz J, Yue S, Xue W. Dental diseases are associated with increased odds ratio for coronavirus disease 19. Oral Dis 2020. https://doi.org/10.1111/odi.13653. [Epub ahead of print].

[24] Roy AS, Matson M, Herlekar R. Response to ‘vitamin D concentrations and coronavirus-19 infection in UK Biobank; Diabetes Metab Syndr 2020;14:777.

[25] Meng JF, Howey KM, Wactawski-Wende J, Andrews CA, LaMonte MJ, Horst RL, et al. Intraindividual variation in plasma 25-hydroxyvitamin D measures of 25-hydroxyvitamin D status and other clinical characteristics with COVID-19 infection in UK Biobank. Diabetes Metab Syndr 2020;14:513.

[26] Hastie CE, Mackay DF, Ho F, Cels-Morales CA, Katiokriedi SV, Niederwieser CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr 2020;14:561–5.

[27] Yancy CW. COVID-19 and African Americans. JAMA 2020;323:1891–2.

[28] Lamsaati E, Pëbay PP, Picard JL, Forget J. Covid-19 and vir-d. Disease mortality: negatively correlates with sunlight exposure. Spat Spatiotemporal Epidemiol 2020;35:100362.

[29] Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Alano JL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths, Nutrients 2020;12:989.

[30] Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome. Lancet Diabetes Endocrinol 2020;8:570.

[31] Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aboof JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583.

[32] National Institutes of Health. Covid-19 treatment guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/vitamin-d. Accessed December 2020.

[33] Mohan M, Cheria M, Sharma A. Exploring links between vitamin D deficiency and COVID-19. PLoS Pathog 2020;16:e1008874.